Last reviewed · How we verify
Nurofen Plus®
Nurofen Plus combines ibuprofen (a nonsteroidal anti-inflammatory drug) with codeine phosphate (an opioid analgesic) to provide enhanced pain relief through dual analgesic and anti-inflammatory action.
Nurofen Plus combines ibuprofen (a nonsteroidal anti-inflammatory drug) with codeine phosphate (an opioid analgesic) to provide enhanced pain relief through dual analgesic and anti-inflammatory action. Used for Moderate acute pain (headache, dental pain, period pain, backache, minor injuries).
At a glance
| Generic name | Nurofen Plus® |
|---|---|
| Also known as | Ibuprofen/Codeine |
| Sponsor | Reckitt Benckiser LLC |
| Drug class | NSAID/opioid combination analgesic |
| Target | COX-1/COX-2 (ibuprofen); mu opioid receptor (codeine) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Codeine phosphate acts as a weak opioid agonist at mu receptors in the central nervous system to enhance analgesia. The combination provides synergistic pain relief for moderate pain that does not respond adequately to either agent alone.
Approved indications
- Moderate acute pain (headache, dental pain, period pain, backache, minor injuries)
Common side effects
- Nausea
- Dizziness
- Constipation
- Drowsiness
- Gastrointestinal upset
Key clinical trials
- A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension (PHASE1)
- Ibuprofen 4% (w/v) Pivotal Bioequivalence Study (PHASE1)
- Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study (PHASE3)
- Ibuprofen Suspension Bioequivalence Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nurofen Plus® CI brief — competitive landscape report
- Nurofen Plus® updates RSS · CI watch RSS
- Reckitt Benckiser LLC portfolio CI